Primary Job Title Chief Medical Officer Primary Organization 
QUE Oncology
Location Orlando, Florida, United States Regions East Coast, Southern US Gender Female
LinkedIn View on LinkedIn
Wendy Chief Medical Officer (CMO) at Ridgeback, overseeing the development of molnupiravir. Having worked on molnupiravir since its discovery, Dr. Painter followed the molecule to Ridgeback. She is a physician executive who has held senior positions in health care and throughout the biopharmaceutical and biotechnology sectors and is a globally
recognized expert in antiviral drug development. Prior to joining Ridgeback, Dr. Painter was a Consultant in Pharmaceutical Medicine in roles from nonclinical development through post-marketing life cycle management, CEO and CMO at QUE Oncology, CMO at Chimerix, Inc (developed Tembexa through Phase 2), and Medical Director at GlaxoSmithKline.
She earned her B.S. and M.S. (Organic Chemistry) at Emory University, an M.D. at the University of Miami School of Medicine, and an M.P.H. at The University of North Carolina at Chapel Hill; after completing an Occupational Medicine Fellowship at Duke University Medical Center she joined the faculty at Duke. Dr. Painter served for a decade on an Institutional Review Board.
